Initiation of antiretroviral therapy (ART) followed appropriate national guidelines (25), and all visits after 77 ART were excluded. Analyses of the remaining longitudinal data targeted three time intervals in SCs, i.e.,
the co-existence frequency expected from a random distribution). In the SP group, the frequency was 132 slightly higher for both, as 38 (13.0%) of them had B*57, 21 (7.2%) had B*81, and two (0.7%) had both.
133
Relationships between timing of data collection and manifestations of HIV-1 infection. In the 134 SC group, virologic and immunologic outcomes showed weak and sporadic correlation with duration of 135 infection (DOI) at three major intervals (peak, set-point, and nadir) within the first 24 months of infection 136 (Table 2) . Correlation with the greatest statistical significance (P <0.0001) was for peak VL and DOI 
164
Viremia as a categorical phenotype in SCs and SPs. Test for trend was also revealing, as HLA-165 B*57 was clearly less frequent in the subgroups of SCs and SPs with high (>100,000 copies/ml) and 166 medium (10,000-100,000 copies/ml) than low (<10,000 copies/ml) VL (Table 3) 
191
Separate analyses of subjects from southern and eastern Africa to assess regional 192 consistency. HLA-related, discordant relationship between VL and immunodeficiency was evident in regardless of country of origin (Table 4) 
228
Compared with HLA-B*57, B*81 is less common, with population frequencies ranging from 229 2.7% in Kenyans, 4.8% in Rwandans, 5.9% in Zambians to 7.1% in Ugandans enrolled into this study.
230
Other rare HLA-B alleles occasionally associated with advantageous outcomes (e.g., B*13, B*27, and 
